



### **Abbreviations**

- All of Us, AoU.
- Ankle-brachial index, ABI.
- Body mass index, BMI.
- Coronary artery disease, CAD.
- Current Procedural Terminology, CPT.
- Diastolic blood pressure, DBP.
- Electronic health record, EHR.
- Genome-wide association study, GWAS.
- Glomerular filtration rate, GFR.
- High-density lipoprotein cholesterol, HDL-C.
- International Classification of Disease, ICD.
- Least Absolute Shrinkage and Selection Operator, LASSO.
- Low-density lipoprotein cholesterol, LDL-C.
- Major adverse limb events, MALE.
- Mass General Brigham Biobank, MGBB.
- Office of Population Censuses and Surveys, OPCS.
- Peripheral artery disease, PAD.
- Polygenic risk scores, PRS.
- Principal components, PCs.
- Research Patient Data Registry, RPDR.
- Systolic blood pressure, SBP.
- United States Preventive Services Task Force, USPSTF.

# **Abstract**





# **Introduction**

 Peripheral artery disease (PAD) is an atherosclerotic vascular condition that affects a global population of 230 million adults with high resource utilization owing to 4 both systemic and limb ischemic events.<sup> $1,2$ </sup> While PAD shares risk factors with coronary artery disease (CAD), 32-54% of individuals presenting with PAD do not have clinically 6 significant coronary or cerebrovascular disease. $3,4$  In addition, there are differences in the major etiologies of acute events in CAD and PAD. Ischemic CAD events most commonly result from plaque rupture, whereas the cause of acute limb ischemia is most commonly owing to embolism or *in situ* thrombosis, regardless of atherosclerosis 10 extent.<sup>5</sup> Indeed, the increasingly recognized role of thrombosis in PAD is also supported by the discovery of genetic variants in coagulation factors, including mutations in Factor 12 V Leiden, which have been uniquely associated with PAD and not CAD.<sup>6</sup> Clinical subsets of PAD include asymptomatic, claudication, and chronic-limb threatening ischemia (CLTI) resulting in tissue loss and major adverse limb events (MALE). MALE are a devastating complication and are often associated with critical illness, numerous resource-intensive attempts at revascularization, and prolonged hospital stays as part of the limb salvage effort. Despite its high morbidity, PAD is grossly underdiagnosed and has a lack of consensus on screening indications. For example, while European and American guidelines recommend consideration of screening based on age and risk factors, the United States Preventive Services Task 21 Force (USPSTF) does not recommend screening regardless of risk factors.<sup>7-9</sup> Conflicting recommendations have implications on care implementation, for example, in 23 the U.S. where preventive service coverage is guided by USPSTF recommendations.<sup>10</sup>



# **Methods**

22 Study populations



Genetic data and quality control

 In the UK Biobank, individuals were genotyped using UK BiLEVE Axiom Array or UK Biobank Axiom Array and centrally imputed to the 1000 Genomes (1000G) Panel, 3 Haplotype Reference Consortium, or UK10K Panel.<sup>17,20</sup> After performing quality control (Details Methods) and excluding individuals of Latino ancestry due to low population representation (N=11 PAD cases) and unreported/mixed ethnicity, 304,294 individuals were included for internal validation.

 MGBB samples were genotyped on Illumina Multi-Ethnic Genotyping Array or Global 9 Screening Array.<sup>21</sup> Imputation was performed to the multi-ancestry TOPMED r2 reference panel. Given lack of detailed self-reported ethnicity or ancestry data, ancestry was genetically predicted using a K-nearest neighbor model trained with principal components (PCs) from the 1000G reference panels for European, African, Latino/Ad 13 Mixed American, East Asian, and South Asian (Detailed Methods).<sup>18</sup> We excluded 14 individuals who were in prior discovery GWAS for  $CAD^{22}$  and did not map to a single genetic ancestry, leaving 37,017 individuals for external validation.

 AoU participants were genotyped using the Illumina Global Diversity Array at AoU 18 genome centers.<sup>23</sup> Similar to the MGBB, there was a lack of detailed reported ancestry data, thus ancestry was assigned based on genetic similarity. AoU assigns categorical ancestries to African, Latino/Ad Mixed American, East Asian, South Asian, European, MENA, and Other based on a random forest classifier trained using gnomAD, Human 22 Genome Diversity Project, and 1000G reference labels (Detailed Methods).<sup>23</sup> After exclusion of individuals with missing/other ancestry, 237,173 individuals were included.

# Clinical endpoints

- In the UK Biobank, PAD was defined based on self-reported history, ICD codes, OPCS
- codes for lower extremity revascularization or major amputation, and cilostazol
- prescription (Supplemental Table 4). In AoU, PAD was defined on self-report,
- occurrences of >2 ICD codes, or a single procedure code for revascularization, major
- 7 amputation or supervised exercise therapy for PAD (Supplemental Table 5). $^{24}$
- 
- In the MGBB, PAD was derived from phenotypes developed by the Mass General

Brigham Research Patient Data Registry (RPDR) based on structured and unstructured

11 clinical data from the EHR (Detailed Methods).<sup>25</sup> ABI were extracted from imaging

reports retrieved from the RPDR. We selected each individual's minimum ABI and

excluded values that were >1.4 or non-compressible.

 MALE was defined as a surrogate of major amputation and acute limb ischemia based on diagnosis and procedure codes (Supplemental Tables 6-8). Revascularization included thrombectomy, thrombolysis, and emergency lower extremity bypass. In the MGBB, CPT codes for catheter-directed thrombolysis/thrombectomy required concomitant coding for aortogram or lower extremity angiography to ensure arterial intervention.

22 GPS<sub>PAD</sub> construction

 PRS predictive performance is improved by the incorporation of data from increasingly 2 diverse genetic ancestries and consideration of genetically correlated traits.<sup>26-28</sup> To leverage the common mechanistic pathways of PAD, other atherosclerotic conditions, and PAD risk factors, GWAS results of PAD and 14 candidate traits were considered in GPSPAD construction: PAD, CAD, ischemic stroke, glomerular filtration rate, diabetes mellitus, smoking, systolic blood pressure (SBP), diastolic blood pressure (DBP), low- density lipoprotein cholesterol (LDL-C), total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, BMI, carotid plaque burden, and carotid intima-media 9 thickness (Supplemental Table 9). After collection of GWAS summary statistics, GPSPAD was trained using target data from 96,239 European individuals in the UK Biobank. 11 GWAS results from the UK Biobank were not used to construct  $GPS_{PAD}$  such that data for score development and training were non-overlapping.

14 GPS<sub>PAD</sub> was developed in a two-layer process (Figure 1).<sup>26</sup> Layer 1 involved using ancestry-stratified GWAS data for each trait to calculate multi-ancestry polygenic scores that were optimized according to their PAD predictive performance. Separate scores were constructed using LDpred2, a widely used method that adjusts marginal single nucleotide polymorphism effect sizes for linkage disequilibrium (LD) patterns and 19 selects a subset of variants with non-zero effects to calculate the polygenic score.<sup>29</sup> Using LDpred2-auto, scores were calculated using GWAS results stratified by African, East Asian, European, Latino, and South Asian ancestry (R bigsnpr v.11.4). This resulted in 100 scores across all ancestries and traits. For each trait, the ancestry-specific scores were combined into the best-performing multi-ancestry score per trait



It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.04.24314847;](https://doi.org/10.1101/2024.10.04.24314847) this version posted October 4, 2024. The copyright holder for this preprint

We also calculated the lifetime risk of PAD in individuals in the UK Biobank based on

- clinical variables using the Johns Hopkins University PAD risk tool
- 3 (http://ckdpcrisk.org/padrisk, Detailed Methods).<sup>31</sup>
- 

#### Statistical analysis

6 The unadjusted rate of PAD was calculated across percentiles of GPS<sub>PAD</sub>. Model

calibration was assessed with the Hosmer–Lemeshow test (R ResourceSelection v0.3-

6) and by comparing the observed and predicted prevalence across percentiles

9 calculated using a logistic regression model with only GPS<sub>PAD</sub> as a predictor. We

10 estimated PAD risk in the extremes of the GPS<sub>PAD</sub> distribution using logistic regression

models. We also derived the proportion of the population with a given magnitude of risk

12 by calculating the odds ratio (OR) of varying extremes of GPS<sub>PAD</sub> percentiles compared

to the middle quintile group (40-59%).

15 The association of GPS<sub>PAD</sub> and other scores with all PAD (incident and prevalent cases) were assessed using logistic regression. Performance metrics included OR, area under the receiver operator characteristic curve (AUC, R pROC v1.17.0.1), and phenotypic 18 variance explained (Nagelkerke- $R^2$ ). Incident event analyses were performed using Cox proportional hazards models with metrics including hazard ratio (HR) and C-statistic (R survival v3.5-7). MALE analyses were restricted to individuals with prevalent PAD diagnoses. Time-to-MALE curves were estimated using the Kaplan-Meier method, standardized to mean age and gender (R survminer v0.4.9). Linear regression was used to evaluate the relationship between polygenic scores and minimum ABI.



was predominantly derived from European discovery data, the score incorporated

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.04.24314847;](https://doi.org/10.1101/2024.10.04.24314847) this version posted October 4, 2024. The copyright holder for this preprint

 genetic variation discovered in African, East Asian, South Asian, and Latino populations (Supplemental Table 10). Of the non-European populations, African GWAS discovery 3 data contributed the most to  $GPS_{PAD}$ .

# 5 Association of GPS<sub>PAD</sub> with PAD risk

6 Within the UK Biobank, GPS<sub>PAD</sub> was associated with a OR 1.77 (95% CI: 1.70-1.86) for PAD in the European training sample (Supplemental Table 12). The effect size was mildly attenuated in the multiethnic validation cohort including 304,294 individuals, but remained strongly associated with PAD (OR 1.63; 95% CI 1.60-1.68). The holdout validation cohort included 164,108 females (53.9%) and 286,356 participants of European (94%), 7,680 South Asian (2.5%), 6,939 African (2.3%), 1,761 East Asian (0.6%), and 1,558 (0.51%) MENA ancestry. There was a decrement, yet persistently significant association with adjustment for clinical risk factors (OR 1.35; 95% CI 1.31- 1.39) and in a model adjusted for continuous covariates (OR 1.37; 95% CI: 1.33-1.41). 16 We found significant differences in PAD rates across the GPS $_{PAD}$  percentile distribution, ranging from 0.78% in the bottom percentile to 7.91% in the top percentile (**Figure 2A,**  Supplemental Table 13). Predicted PAD prevalence was overall consistent with observed prevalence, excluding the >98% percentile where there was slight risk 20 underestimation by GPS<sub>PAD</sub> alone driven by a sharp increase in the observed PAD 21 prevalence (Supplemental Figure 1).  $GPS_{PAD}$  stratified individuals in low and high-risk 22 groups with up to 4.71-fold increased PAD risk in the top 1% of GPS<sub>PAD</sub> (OR 4.71, 95%) CI 4.07-5.42) compared to the middle quintile (**Figure 2B**).









21 incident disease as the high-risk groups that current guidelines recommend screening

22 for PAD.<sup>8</sup> We first quantified the 10-year incidence of PAD among subgroups of

23 individuals proposed to be candidates for ABI screening according to the AHA/ACC

1 Guidelines.<sup>8</sup> Individuals above 65y had a 10-year incidence of 2.28% (95% CI 2.16- 2.41), individuals who were age 50-64y with one risk factor for atherosclerosis had an incidence of 1.23% (95% CI 1.17-1.30%), individuals <50y with diabetes and 1 additional risk factor had an incidence of 2.90% (95% CI 1.62-3.21%), and those with known atherosclerosis in another vascular bed had the greatest incidence of 5.95% (95% CI 5.48-6.42). As a comparison, incidence rates ranged from 2.81-4.40% in the 7 top 1-5% GPS<sub>PAD</sub> compared to the middle quintile distribution (Supplemental Table 16). We also looked at age-based combinations of each individual risk factor and compared event rates to subgroups with the combination of risk factors and high polygenic risk. 10 This analysis revealed that the combination of high GPS<sub>PAD</sub> with one atherosclerosis risk factor identified more individuals who subsequently developed PAD than many of the subgroups defined by the combination of similar risk factors with age (**Figure 5A)**. 13 For example, 7.96% of individuals in the top 5% GPS<sub>PAD</sub> and diabetes developed PAD, as compared to a 4.02% incident rate among individuals aged 50-64y with diabetes. Similarly, there was a relative increase in PAD cases among individuals in the top 5% 16 GPS<sub>PAD</sub> with dyslipidemia  $(5.63\%; 95\% \text{ CI } 4.88-6.36)$  compared to individuals 50-64y 17 with dyslipidemia  $(1.97\%; 95\% \text{ C}11.80-2.15)$ . The addition of the top 5% GPS<sub>PAD</sub> also increased the proportion of additional cases of PAD when combined with other atherosclerotic conditions such as CAD and carotid stenosis compared to consideration of the conditions alone (Supplemental Table 16).

### Predicting ankle-brachial indices based on polygenic risk







1 related risk factors to enhance genetic risk prediction. Such approaches that incorporate genome-wide genetic correlation increase the power of polygenic association analyses and improve prediction accuracy.<sup>36,37</sup> GPS<sub>PAD</sub> was indeed the most strongly predictive of PAD risk in external validation cohorts. Unlike previously published 5 polygenic scores, GPS<sub>PAD</sub> was able to predict PAD risk in Latino individuals in All of Us and both African and South Asian individuals in two distinct cohorts (All of Us and the UK Biobank).

8 In prospective analysis in the UK Biobank, GPS<sub>PAD</sub> was associated with incident 9 PAD with similar effect sizes as cross-sectional analysis. The inclusion of GPS<sub>PAD</sub> resulted in a comparable benefit in discriminative capacity as those afforded by smoking 11 and diabetes.<sup>3</sup> We also note a significant interaction between GPS<sub>PAD</sub> and LDL-C or hemoglobin A1c in models predicting incident PAD. This suggests that individuals with 13 higher GPS<sub>PAD</sub> may have a greater benefit from dietary changes, statin therapy, or glycemic control. Indeed, post-hoc analyses of statin therapy trials demonstrate that statins confer a greater cardiovascular risk reduction in those with high genetic risk 16 compared to the general population.

 Current European guidelines more broadly recommend consideration of screening based on age and cardiovascular risk factors, while American cardiovascular society guidelines recommend screening for PAD with ABI in four groups: age>65 years, age 50-64 years with atherosclerotic risk factors, age <50 years with diabetes 21 and 1 risk factor, and history of atherosclerosis in other vascular beds. $8,9$  Addition of the 22 GPS<sub>PAD</sub> has the potential to further streamline these screening recommendations and identify higher risk populations. When evaluating the combination of polygenic risk and

 clinical risk assessment, incorporation of the top 5% polygenic risk with conventional risk factors identified more individuals who went on to develop PAD compared to the combination of risk factors with age. These results suggest the top 5% genetic risk and presence of risk factors could be considered a criteria for screening with ABIs to establish PAD diagnosis. Indeed, when leveraging ABIs, our analysis revealed an ABI 6 diagnostic of PAD associated with high GPS $_{\text{PAD}}$  in the MGBB, although replication in other cohorts is needed.

 Secondary prevention efforts in PAD focus on limb salvage. MALE are associated with poor prognosis for PAD patients and represent index events for subsequent hospitalizations, reinterventions, major adverse cardiac events, and even 11 mortality.<sup>39</sup> Once acute limb ischemia occurs, numerous returns to the operating room for revascularization with combined exposure to anticoagulation and thrombolytic therapy and subsequent reperfusion is a major physiologic stress in an already comorbid patient population. Staging systems such as the Wound, Ischemia, and foot Infection are used to determine amputation risk in the CLTI population, but there are no 16 current vetted clinical tools for predicting MALE early in the disease course.<sup>3</sup> Our 17 analysis found that  $GPS_{PAD}$  stratified MALE risk specifically in the PAD population and remained consistently predictive of incident MALE in the UK Biobank, Mass General Brigham Biobank, and All of Us.

 These findings have several implications. First, an individual's genetic risk in combination with their cardiovascular risk factor profile may be employed as a criteria for consideration of screening with non-invasive vascular testing. PAD is an underdiagnosed and undertreated condition with guideline-directed therapies that lag

1 that of CAD.<sup>8</sup> Incorporation of polygenic risk may be used as an adjunct to clinical risk assessment to identify a greater proportion of high-risk individuals for medical 3 optimization. In addition, as with studies of polygenic risk and  $CAD^{38,40-42}$ , there may be early benefits for targeted intensive lifestyle and risk factor optimization in PAD with high genetic risk. However, there is need for further testing the effect of polygenic scores on hard cardiovascular outcomes in prospective studies, particularly among younger age 7 groups. Given that high GPS<sub>PAD</sub> was strongly associated with MALE in three distinct PAD cohorts, there is promise for implementation of polygenic scores into secondary prevention measures for vascular practitioners, such as in frequency of surveillance or guiding more aggressive or prolonged antithrombotic therapies shown to reduce MALE 11 incidence.<sup>11,39</sup>

12 Our study has several limitations. First, GPS<sub>PAD</sub> was trained using data from largely European individuals due to limitations in sample size of other ancestries. Nevertheless, we demonstrated evidence of portability to non-European groups, not previously achieved by prior PAD polygenic scores. Second, this study was restricted to individuals with genetic similarities to single ancestries and had more limited cases of non-European groups, which could have limited power to detect associations especially among the East Asian and MENA groups. Race alone was importantly not used to infer ancestry, however such broad ancestral categorizations can mask heterogeneity in polygenic score performance in some groups. Tailoring of polygenic scores to non- European target data, continued recruitment of underrepresented populations in biobanks, and development of methods to account for admixture should be a priority to improve polygenic score performance. Lastly, PAD and MALE phenotyping were based

 on diagnosis and procedures codes from the EHR. There could have been variation in the quality of definitions between cohorts that influenced analyses towards null associations. However, we used non-invasive studies in the MGBB as another surrogate for PAD and observed similar associations of polygenic risk with binary PAD classifications in both the MGBB and AoU, where the latter is comprised of several U.S. healthcare institutions.

### **Ethics Approval**

 Individuals in the UK Biobank, All of Us, and Mass General Brigham Biobank underwent signed consent for genetic sequencing, storage of biological specimens, and access to electronic health record data. This research was conducted using the UK Biobank resource under application number 7089. Secondary analyses of the UK Biobank, MGBB, and AoU was approved by the Massachusetts General Hospital Institutional Review Board.

#### **Data Availability**

 Individual-level data from the UK Biobank and All of Us are available upon request from researchers to each organization. This study used Controlled Tier data from All of Us 19 which is available to authorized users on the All of Us Researcher Workbench. GPSPAD constructed in this paper will be made available in the Polygenic Score Catalog following publication. Polygenic scores used for comparison of GPSPAD performance are available in the Polygenic Score Catalog through accession ID PGS001843 and PGS002055.

### 

### **Acknowledgments**

- We thank the participants and investigators in the UK Biobank, All of Us, and Mass
- General Brigham Biobank for their contributions to this study.
- 

# **Funding**

- This work was supported by the Harvard Medical School LaDue Fellowship in
- Cardiovascular Medicine (to A.M.F.) and National Institutes of Health (grants
- R01HL127564 and U01HG011719 to P.N. and K08HL168238 to A.P.P.).

### **Disclosure of Interest**

 P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, Merck, and Novartis, scientific advisory board membership of Esperion Therapeutics, Preciseli, TenSixteen Bio, and Tourmaline Bio, scientific co-founder of TenSixteen Bio, equity in MyOme, Preciseli, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. All other authors have no relevant disclosures.

- 
- 

#### **References:**

- 1. Song P, Rudan D, Zhu Y*, et al.* Global, regional, and national prevalence and risk
- factors for peripheral artery disease in 2015: an updated systematic review and
- analysis. *Lancet Glob Health* 2019;**7**:e1020-e1030. doi: 10.1016/S2214-
- 109X(19)30255-4
- 2. Mahoney EM, Wang K, Keo HH*, et al.* Vascular hospitalization rates and costs in
- patients with peripheral artery disease in the United States. *Circ Cardiovasc Qual*
- *Outcomes* 2010;**3**:642-651. doi: 10.1161/CIRCOUTCOMES.109.930735
- 3. Aday AW, Matsushita K. Epidemiology of Peripheral Artery Disease and
- Polyvascular Disease. *Circ Res* 2021;**128**:1818-1832. doi:
- 10.1161/CIRCRESAHA.121.318535
- 4. Hackler EL, 3rd, Hamburg NM, White Solaru KT. Racial and Ethnic Disparities in
- Peripheral Artery Disease. *Circ Res* 2021;**128**:1913-1926. doi:
- 10.1161/CIRCRESAHA.121.318243
- 5. Narula N, Olin JW, Narula N. Pathologic Disparities Between Peripheral Artery
- Disease and Coronary Artery Disease. *Arterioscler Thromb Vasc Biol* 2020;**40**:1982-
- 1989. doi: 10.1161/ATVBAHA.119.312864
- 6. Klarin D, Lynch J, Aragam K*, et al.* Genome-wide association study of peripheral
- artery disease in the Million Veteran Program. *Nat Med* 2019;**25**:1274-1279. doi:
- 10.1038/s41591-019-0492-5
- 7. Mills J, Duffy M. Screening for Peripheral Artery Disease and Cardiovascular
- Disease Risk Assessment with the Ankle-Brachial Index. *Am Fam Physician*
- 2018;**98**:754-755. doi:





- 21. Boutin NT, Schecter SB, Perez EF*, et al.* The Evolution of a Large Biobank at
- Mass General Brigham. *J Pers Med* 2022;**12**. doi: 10.3390/jpm12081323
- 22. Aragam KG, Jiang T, Goel A*, et al.* Discovery and systematic characterization of
- risk variants and genes for coronary artery disease in over a million participants. *Nat*
- *Genet* 2022;**54**:1803-1815. doi: 10.1038/s41588-022-01233-6
- 23. All of Us All of Us Genomic Quality Report
- https://support.researchallofus.org/hc/en-us/articles/4617899955092-All-of-Us-
- Genomic-Quality-Report-
- 24. Yu S, Ma Y, Gronsbell J*, et al.* Enabling phenotypic big data with PheNorm. *J Am*
- *Med Inform Assoc* 2018;**25**:54-60. doi: 10.1093/jamia/ocx111
- 25. Castro VM, Gainer V, Wattanasin N*, et al.* The Mass General Brigham Biobank
- Portal: an i2b2-based data repository linking disparate and high-dimensional patient
- data to support multimodal analytics. *J Am Med Inform Assoc* 2022;**29**:643-651. doi:
- 10.1093/jamia/ocab264
- 26. Patel AP, Wang M, Ruan Y*, et al.* A multi-ancestry polygenic risk score improves
- risk prediction for coronary artery disease. *Nat Med* 2023;**29**:1793-1803. doi:
- 10.1038/s41591-023-02429-x
- 27. Ruan Y, Lin YF, Feng YA*, et al.* Improving polygenic prediction in ancestrally
- diverse populations. *Nat Genet* 2022;**54**:573-580. doi: 10.1038/s41588-022-01054-7
- 28. Patel AP, Khera AV. Advances and Applications of Polygenic Scores for
- Coronary Artery Disease. *Annu Rev Med* 2023;**74**:141-154. doi: 10.1146/annurev-med-
- 042921-112629





### **Legends**

#### **Figure 1. Schematic of GPSPAD construction and study design.**

- 3 1A. Overview of GPS<sub>PAD</sub> development using GWAS summary statistics for PAD and 14
- related traits stratified by African, East Asian, European, Latino, or South Asian
- ancestry.
- 1B. GPSPAD was then evaluated in three validation datasets consisting of distinct,
- ancestrally diverse individuals, with outcomes including PAD (prevalent and incident),
- ankle-brachial indices, and MALE. Diagram designed with FreePik. AFR, African. EAS,
- 9 East Asian. EUR, European. LAT, Latino. LD<sub>ref,</sub> ancestry-matched LD reference panel.
- MENA, Middle Eastern/North African. SAS, South Asian.
- 

**Figure 2: GPSPAD is an integrated polygenic score that stratifies PAD risk in** 

#### **diverse ancestries**

- 14 2A. Prevalence of PAD across GPS<sub>PAD</sub> percentiles in the UK Biobank validation dataset
- 15  $(N = 304,294)$ .
- 16 2B. Estimated PAD risk in the top and bottom of  $GPS_{PAD}$  percentile distributions relative
- to the middle quintile (40-59%), as assessed in logistic regression models adjusted for
- age, sex, genotyping array, and ten principal components of ancestry. Results are
- shown on log-axis.
- 20 2C. Risk of PAD associated with GPS<sub>PAD</sub> in ancestral subgroups in the UK Biobank.
- Results were calculated from a logistic regression model with age, sex, genotyping

array, and ten principal components as covariates.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.04.24314847;](https://doi.org/10.1101/2024.10.04.24314847) this version posted October 4, 2024. The copyright holder for this preprint

#### **Figure 3. GPSPAD shows improved transferability to external cohorts.**

- 4A. OR per-SD change of polygenic scores in external validation cohorts, AoU (N =
- 237,173) and MGBB (N = 37,017).
- 4B. Predictive performance for each score is also shown in ancestry subgroups: African
- 5 individuals in AoU ( $N = 51,691$ ) and MGBB ( $N = 1,945$ ); East Asians in AoU ( $N = 5,268$ ),
- 6 European individuals in AoU ( $N = 119,167$ ) and MGBB ( $N = 32,139$ ); Latino individuals
- 7 in AoU ( $N = 39,576$ ) and MGBB ( $N = 2,933$ ); and South Asian individuals in AoU ( $N =$
- 2,289).
- OR were calculated from a logistic regression model adjusted for age, sex, genotyping
- array, and the first ten principal components. Asterisks represent P-value for
- associations, \*=P<0.05. \*\*=P<0.01. \*\*\*P<0.0001.
- EAS, East Asian. EUR, European. LAT, Latino. SAS, South Asian.
- 

#### **Figure 4. Performance of GPSPAD in predicting incident PAD in the UK Biobank.**

15 4A. Changes in C-statistic of  $GPS_{PAD}$  (red point) and clinical risk factors (blue points)

relative to the baseline model including age, sex, and the first ten principal components

of ancestry (gray point), as calculated from Cox proportional hazards models in the UK

- Biobank holdout validation dataset. Lines represent confidence intervals of the C-
- statistic change.
- 4B-C. 10-year rates of PAD according to lifestyle and genetic categories, showing the
- influence of smoking (4B) and dietary patterns (4C). Shown are standardized
- cumulative rates of incident PAD standardized to the population averages for each
- covariate in the Cox models.



- models including age, sex, genotyping array, the first ten principal components of
- ancestry as covariates.
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 



#### **Validate PAD prediction performance in 3 distinct populations**



## Assess utility of GPS<sub>PAD</sub> in guiding screening and secondary prevention



- Assess magnitude of risk discrimination ability for incident PAD
	- Evaluate relationship of GPS $_{PAD}$  with ankle-branchial indices
	- Test association of GPS $_{PAD}$  with incident MALE in prevalent PAD

Figure 2





Figure 3 It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2024.10.04.24314847;](https://doi.org/10.1101/2024.10.04.24314847) this version posted October 4, 2024. The copyright holder for this preprint<br>(**which was not certified by peer review)** is the author/funder, who has grante



Figure 4







medRxiv preprint doi: [https://doi.org/10.1101/2024.10.04.24314847;](https://doi.org/10.1101/2024.10.04.24314847) this version posted October 4, 2024. The copyright holder for this preprint<br>(**which was not certified by peer review)** is the author/funder, who has grante It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . Figure 6

